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Abstract
Introduction and Aims Experiences of buprenorphine‐naloxone (BNX) sublingual film injection are not
well documented or understood. We examined how people who inject BNX film seek and share information
about this practice, document the methods used to prepare BNX film for injection, and report participants'
experiences of this practice. Design and Methods Interviews were (n = 16) conducted with people who
indicated that they had injected BNX film since its introduction onto the Australian market. Semistructured
interviews were recorded and transcribed. NVivo10 program (QSR International) was used to analyse the
data using qualitative description methodology. Results Participants largely reported similar BNX film
preparation techniques, although the texture of BNX film during preparation to inject was reported to be
unusual (gluggy), and there were many varied accounts associated with the amount of water used. Physical
harms reported as associated with injecting BNX film were described (including local and systemic issues);
participants reported injecting the film to enhance its immediate effects, yet generally reported that sublingual
administration provided longer‐lasting effects. Discussion and Conclusions Understanding knowledge
acquisition about injecting new formulations of opioid substitution therapy is crucial in developing more
effective harm‐reduction strategies. Dissemination by peer networks to those who are currently or planning to
inject BNX film regarding the 'gelatine like' texture when mixing, using only cold water and double filtering is
important to ensure safer injecting practices. Findings from this study highlight the importance of peer
networks for the dissemination of harm‐reduction information. Introduction of new formulations
internationally requires more qualitative studies to inform safer practices.
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Introduction and Aims: Experiences of buprenorphine-naloxone (BNX) sublingual film 
injection are not well documented or understood. We examined how people who inject BNX 
film seek and share information about this practice, document the methods used to prepare BNX 
film for injection, and report participants’ experiences of this practice.  
Design and Method:  Interviews (n=16) conducted with people who indicated that they had 
injected BNX film since its introduction onto the Australian market. Semi-structured interviews 
were recorded and transcribed. NVivo10 program (QSR International) was used to analyse the 
data using Qualitative Description methodology. 
Results: Participants largely reported similar BNX film preparation techniques, although the 
texture of BNX film during preparation to inject was reported to be unusual (gluggy), and there 
were many varied accounts associated with the amount of water used. Physical harms reported as 
associated with injecting BNX film were described (including local and systemic issues); 
participants reported injecting the film to enhance its immediate effects, yet generally reported 
that sublingual administration provided longer-lasting effects.  
Discussion: Understanding knowledge acquisition about injecting new formulations of OST is 
crucial in developing more effective harm reduction strategies. Dissemination by peer networks 
to those who are currently or plan to inject BNX film regarding the ‘gelatine like’ texture when 
mixing, using only cold water, and double filtering is important to ensure safer injecting 
practices.  
Conclusions: Findings from this study highlight the importance of peer networks for the 
dissemination of harm reduction information. Introduction of new formulations internationally 
requires more qualitative studies to inform safer practices. 
Key words: Patient non-adherence, buprenorphine-naloxone, qualitative research, harm 






Medicines, including those used to treat opioid dependence, have an important, legitimate role in 
medical practice, and can make an enormously positive contribution to the health and wellbeing 
of many patients (1). However, not all pharmaceuticals are used in accordance with doctors’ 
directions. The injection of pharmaceutical products developed for oral or sublingual 
consumption has been well described in the literature, and this practice has been associated with 
a number of individual physical harms (2-6). Notably, the introduction of newer “abuse-
deterrent” formulations may result in a range of serious and unanticipated harms. Two examples 
of this include the introduction of the gel cap formulation of Temazepam©, resulting in a range of 
injection related harms such as thrombophlebitis, abscesses and deep venous thrombosis (7), and 
the introduction of a less injectable oxycodone formulation in the US, leading to a significant 
drop in OxyContin injection, with a concurrent doubling in reported rates of heroin use in some 
populations (8). 
Opioid substitution therapy (OST) for opioid dependence predominantly involves the use of 
methadone or buprenorphine, and has been found to be effective in reducing mortality, HIV 
transmission, crime, and other drug use (9-12).  In Australia, OST is usually prescribed under the 
conditions of supervised dosing.  Despite the high level of supervised dosing and, in the case of 
buprenorphine, the predominant use of the buprenorphine-naloxone (BNX) products, the 
diversion and injection of buprenorphine has been documented in both those receiving OST and 
also out of treatment populations (13-15). One Australian study estimated that approximately 9% 
of all ‘supervised doses’ of BNX are removed from clients’ mouths at the dosing point (13), a 
proportion of which are later injected. Several international studies have also reported the nature, 
extent and consequences of injecting BPN (e.g. 3, 16, 17-22).   
In late 2011, a new formulation of sublingual BNX registered as Suboxone Film, was introduced 
in Australia for the treatment of opioid dependence, with the main clinical rationale being to 
reduce aberrant use of BNX.  Previous Australian research has highlighted the difficulties of 





minutes for full dissolution of tablets (23).  One randomised-controlled trial has found that BNX 
film adheres to the sublingual mucosa more rapidly and dissolves faster than BNX tablets, 
particularly at high doses (24). US data from 2011-2012 showed that “abuse and diversion” of 
BPN and BNX tablets exceeded that of BNX film (25). Given these characteristics, it was hoped 
in Australia that BNX film may be (a) quicker to supervise and (b) more difficult to remove from 
the mouth than BNX tablets, resulting in less removal of supervised doses from the dosing site 
and subsequent diversion or injection of supervised doses in comparison to BNX tablets.    
The introduction of the BNX film formulation in Australia has presented a unique opportunity to 
examine the transmission of knowledge and behaviours between people who inject 
pharmaceutical opioids intended for oral or sublingual consumption. This study was undertaken 
as part of a larger mixed-methods post-marketing surveillance study to monitor the extent of 
diversion and injection of BNX film in Australia (26). To date, no qualitative studies have 
examined the context, extent and nature of BNX film injection. Given the potential for severe 
harms associated with the injection of pharmaceutical opioids intended for oral/sublingual 
consumption, understanding how information about injecting new formulations is learned and 
shared is crucial in understanding how best to disseminate harm reduction information and target 
interventions.  Specifically, this study’s aims were: 
a. To examine how people who inject BNX film seek and share information about this 
practice, and  
b. To document the methods used to prepare BNX film for injection and participants’ 
experiences.   
 
Method 
This qualitative study was undertaken as part of a larger mixed-methods post-marketing 
surveillance study of the diversion and injection of BNX film (27).  Qualitative research 
interviews with 16 people who reported injecting BNX film were conducted by trained 





introduction of the Film in Australia.  Participants were recruited from among people currently in 
OST and recruited into the wider post-marketing surveillance studies of BNX film across three 
sites (Adelaide, Sydney, and Melbourne).  Participants reflected the range of treatment settings 
and included a mix of public, private and general practice prescribers.   Participants who 
indicated they had injected BNX film in the post-marketing surveillance interview and who 
indicated that they were willing to participate in another interview regarding BNX injecting were 
approached.  All those approached consented to participate in the study which included a 
recorded face to face interview.    
 
Measures 
Participants were surveyed using a semi-structured interview schedule, with the interview 
recorded and then transcribed. Questions included commencement of injection of various OST 
medications, and more specifically questions focussed on BNX Film including: recent frequency 
of use, acquisition practices, preparation for injection, reasons for and experiences with injecting, 
sublingual use compared to injection, knowledge procurement, and concerns. These questions 
were designed to elicit narratives around injection of BNX film more generally. 
 
Procedure 
Eligible participants were invited to participate in an interview specifically relating to injection 
practices with BNX film. Interviews were conducted at cafes or in an office location 
(independent of OST services) and all participants provided informed consent to be interviewed 
and recorded. Participants were reimbursed either a $40 voucher (NSW, SA) or $40 cash (VIC) 
for their time and travel expenses, with interviews taking approximately 40 minutes.  
 
Ethical approval 
Approval for the qualitative interviews of people who inject BNX film was provided by the 





South Wales HREC, Alfred Hospital HREC and the University of Adelaide HREC. The study 
conforms to the provisions of the Declaration of Helsinki (as revised in Tokyo 2004). 
 
Data Analysis 
Data analysis was conducted using the NVivo10 program (QSR International.). To ensure 
consistency, a selection of early transcripts was reviewed independently by three researchers. 
The analysis involved the use of qualitative description (28) where participants’ responses were 
coded by question responses, and subcategories of coded data were derived by grouping the 
experiences of the participants. Qualitative description does not involve interpretation of the data 
using themes rather it describes what the participant has stated during interviews, and allows for 
understanding of a topic from the participants’ viewpoint and “entails a kind of interpretation 
that is low inference, or likely to result in easier consensus among researchers” (29). Content 
analysis of this nature allows an intense examination of language conducive to “classifying large 
amounts of text into an efficient number of categories that represent similar meanings” (30).  
This methodology is well-suited to research which seeks to examine health behaviours (31). 
Similarities and differences in participants’ responses to the various questions posed were 
examined. Descriptive statistics are also provided for demographic characteristics and details of 
current opioid treatment. 
 
Participants 
Sixteen participants were interviewed. Most participants were male (n=13, 81%), with an 
average age of forty years (range 20-56 years). Participants were mainly unemployed (11 of 16, 
or 69%), spending an average of 10 years in education (range 7-12 years) and living in rental 
accommodation. The majority (n=13, 81%) were receiving opioid substitution treatment (OST) 
at the time of interview (twelve receiving BNX film and one receiving methadone). Participants 
prescribed BNX reported an average 16mg buprenorphine daily (range 8-32mg) at the time of 






Frequency of injection 
Six participants reported injecting BNX film daily (five reported >5 times a day), two reported 
weekly use, three participants reported occasional use (once per month or less), and five had 
injected at least once. 
 
Knowledge Acquisition 
Participants reported a variety of sources for learning how to inject the film with most (56%, 
n=9) through the injecting networks of friends and acquaintances, either through being told how 
to do so (P3, n=6), or by observing others’ practices (P11, n=3).  
I learnt from my mate how to do it, ah, not a mate as much an acquaintance and 
they, pretty much just said, what I do is basically the same drill as you would mix 
up you know anything (P3). 
I learnt through watching my friends, again, just they were using a lot more than 
I was. (P11). 
Five of the participants reported following the advice given, and as can be seen in the extract 
above one was told to continue with their usual practice (P3). One participant reported first 
watching friends and then one of those friends “recommending that I not try a lot at once so they 
only cut a quarter off the film and gave it to me (p11).” This person had just taken prescribed 
Methadone and reported going into precipitated withdrawal immediately after injecting BNX 
film. 
Other participants (44%, n=7) cited experimentation (P13; n=3) and personal experience (P14; 
n=4) as their primary source of knowledge, for example: 
I just tried it again, yeah, and put a lot of water with it because I tried to put a 
little bit of water with it but it went to like a jelly sort of thing so I put a bit extra 





Just personally through injecting pills and heroin and that, just sort of translated 
to that (P14). 
The Internet was also identified as a source of ‘extra’ information regarding injection of BNX 
film by two participants:  
I was mainly checking (the Internet) to find out whether you could inject it you 
could say whether it was injectable or whether people had withdrawals, bad 
withdrawals from it ... The posts on the net could tell you whether you’re able to 
do it (P4). 
Both participants who investigated intravenous use of BNX film via the Internet also asked 
friends (n=1), and used their own personal experience (n=1). One participant mentioned hearing 
through the ‘grapevine’, with another commenting that a number of people had approached him 
asking how to inject it. 
 
Preparation of the BNX film for injection 
Participants provided mixed accounts of the ease with which the film may be dissolved.  The 
general impression given by participants is that BNX film dissolves quite readily in water, 
usually with a spoon or the syringe plunger to mix it up (75%, n=12), with comments such as 
“dissolves quite readily, mix it with the plunger” (P16), and “Put into syringe add hot water and 
keep shaking until dissolved” (P5) describing the process. There was consistency across the 8 
participants who reported that BNX film becomes ‘gluggy’, or gelatine-like when wet, either in 
the mouth via the saliva or when water is added to inject.   This included 4 participants who also 
reported it dissolved readily in water, with comments made such as “[The BNX film] is like 
chewing gum” (P14), “[the BNX film] goes all yucky when wet/ turns into gel” (P13) and “bit 
more viscous than water/ orangey white solution” (P16).  
The majority of participants reported only injecting a ‘dry’ BNX film dose (never been in 
someone’s mouth, 94%, n=15) rather than a ‘wet’ dose (removed from the mouth). A number of 





(40%) used unheated water. One participant reported using lukewarm water when mixing ‘wet’ 
BNX film and unheated water when mixing with ‘dry’ BNX film. The temperature of the water 
did not appear to affect the gelatine-like nature of the film with: four (50%) of those participants 
reporting this phenomenon not heating the water; and, two (25%) of those who reported it mixed 
readily not heating the water.  
Reports regarding the volume of water required varied considerably across the sample.  Several 
participants (5 of 8) noted that with low volumes of water the substance became ‘gelatine like’ 
requiring the addition of more water to dilute the mixture (e.g. around 80 to 100 units in total of 
water for 2-4mg film). However, participants also reported the BNX film dissolved readily using 
less water (e.g. 40-50 units in total for 2-4mg of film).   
Twelve (75%) participants reported using a filter: either a cigarette filter (44%, n=7) or cotton 
wool (25%, n=4) and one did not mention the kind of filter used. It should be noted that all of 
those reporting gelatine like characteristics had used a filter of some form, whereas only 4 (50%) 
of those not reporting such characteristics using filters. The excerpt below was a typical 
description on the process of BNX Film preparation prior to injection: 
I just put it in water, just like you would heroin or Suboxone or anything like 
that…used a filter to mix it around ‘til it was a different colour, and mixed it 
around and then just sucked it up, filtered it with a cigarette filter and just shot it 
up…I didn’t heat it at all. Just mix up by itself, it kind of goes like a chewing gum 
as you mix it (P14). 
 
Experiences with BNX film injecting   
Participants were asked if they had noticed any differences between the experiences of using 
BNX film sublingually compared to injecting it. Around half of the participants who commented 
(57% or 8 of 14), reported that injecting BNX film provided a more rapid or immediate effect 
than sublingual use: 





feel better quickly …it just makes you feel better a whole lot quicker because 
otherwise [taking it sublingually] you’ve got to wait an hour to two hours for it to 
kind of really make you feel better (P15). 
Half of those who reported rapid effects used BNX film daily, with others reporting occasional 
use (n=2), weekly use (n=1) and single use (n=1). 
In the excerpt below, the participant stated that the medication works better when used 
sublingually or as directed (43%; or 6 of 14): 
I think it might makes you hang out quicker [When injected]…Under my mouth it 
lasts longer and it’s better…like I said after that though it wears out 
easier…‘cause I’d wake up in the morning better fresher and I go get my dose 
easier if I had it under my tongue (P8). 
Five participants, of whom three had used daily, did describe feeling slightly different in their 
mood state or in their bodily experience after injection of BNX film. For example participants 
described getting a “little perk, like more energy” (P4), or a “tingling sensation and motivate you 
in that sense” (P5). Other participants (n=2) reported no physical difference between sublingual 
or intravenous administration of BNX film. 
 
Adverse effects arising from injecting BNX film  
Eleven participants (69%) reported some concerns (and some (n=4) reported more than one 
concern regarding physical health and veins issues) arising from injecting BNX film. Issues 
included problems with local injecting sites (55%, n=6); broader health concerns such as 
perceived heart disturbance and puffy hands (37%, n=4); precipitated withdrawal from injecting 
BNX film after using other opiates (e.g. Within a short time my world was coming to end for all I 
knew I thought it was and I was terrified (P11)(20%, n=3)); and, having a ‘dirty hit’ which was 
assumed to be the result of injecting a dose that had come from someone’s mouth (13%, n=2). 





Destroys your veins, absolutely destroys your veins. Use a vein once and that’s it, 
it has gone for two weeks, and then it’s narrowed and it’s clogging and if you use 
it too often it’s gone completely. I have got no usable veins in my arms or hands 
at all. (P1). 
P1 had previously stated that injection of Subutex tablets had destroyed his veins. Of the six 
participants who reported local injecting site issues, five reported that they had also had previous 
veins issues when injecting Subutex.  
Two participants who mentioned having vein problems also reported having chest pain after 
injecting BNX film with both providing similar narratives, for example:  
I was worried for about one week because the section near my heart where I can 
actually feel, it feels like it’s put a resin, a line, a gunky line going into the heart. 
I could actually feel that for the last 3 or 4 days …I’m assuming that it has worn 
off it’s coming off my body which is very happy, because I was worried about 
having a heart attack or something (P4). 
Both participants reported frequent injection of BNX film (2-5 times a day). Neither of 
these participants sought help for their chest pain symptoms, nor did those who had been 




This qualitative study examined the experiences of people who had injected BNX film across 
three Australian jurisdictions at a time when BNX film was being introduced. Our study found 
that, consistent with previous studies examining knowledge transfer (32, 33), friends and other 
people who inject drugs remained the most common source of knowledge regarding injecting 
new pharmaceutical preparations, either by verbal instruction or direct observation (34). 
Experimentation (35) and prior personal experience of injecting other substances were also 





times be associated with the potential for harm – for example, nearly two-thirds of participants 
reported heating their film-water solution prior to injecting – yet  recent laboratory findings 
suggest heating pharmaceutical opioids may result in greater particulate matter, and increase the 
risk of thrombosis or infection (36). The internet still does not appear to be a common source of 
such specific injecting information in this group of individuals.  
We also found that participants across sites reported similar preparation techniques, with 
dissolution in water (either heated or unheated) and filtering using cigarette or cotton filters. Our 
finding that wheel filters were not commonly used represents one opportunity to target harm 
reduction messages to those who inject BNX film, as a double filtering process including a 
wheel filter has previously been shown to be optimal for other pharmaceutical opiates (30). Half 
of the participants noted that when mixing the BNX film preparation it became ‘gelatine like.’ 
This finding is not surprising considering the BNX film consists of hydroxypropyl 
methylcellulose, a thickener which is soluble but viscous in cold water, and virtually insoluble in 
a mixture of hot water and alcohol (37).  There were however many and varied accounts of the 
effects of different volumes of water on the solution such that it is difficult to establish a reliable 
pattern. The findings from this study, taken in context of the existing evidence suggesting that a 
greater volume of water may reduce morphine crystallisation, indicates that harm reduction 
messages should include specific information about volume of water and temperature of water 
when preparing BNX film for injection (30).  
Most participants reported injecting the film to enhance its immediate effects, either for more 
rapid onset, or greater intoxication, but participants generally reported that sublingual 
administration provided longer-lasting effects. These are consistent with expected 
pharmacokinetic effects of different routes of administration (38). Over two thirds of participants 
reported experiencing problems with injecting BNX film including vein issues, precipitated 
withdrawal, heart concerns and dirty hits. None of those reporting cardiac symptoms or 
precipitated withdrawal sought medical assistance, and importantly, participants reported a 





symptoms. This provides further evidence for concerns raised about the barriers to seeking help 
for people who inject drugs, especially those who inject their own take-away prescribed OST 
(34-36). 
These findings reinforce the important role of peer-based education strategies in reducing 
potential harms associated with injecting the BNX film and a need to disseminate this 
information to users (33, 39, 40). Although the safest route of administration is sublingual, 
information needs to be tailored to those who inject BNX film.  Such advice could include using 
only cold water and double filtering to minimise the injection of the ‘gelatine-like’ texture, 
microbes and other particulate matter.  Low threshold services such as needle and syringe 
programs and peer based services provide opportunities to deliver harm reduction advice to this 
target group (39, 40). In some countries, injectable opioid treatment options are available for 
those clients unable or unwilling to cease injection (37, 38). 
A limitation of this study was the small sample size and exploratory in nature of the study, and 
the heterogeneity of prescribing practice across the jurisdictions; that is, each jurisdiction was in 
a different phase of rolling out BNX film as an OST alternative to buprenorphine-naloxone 
tablets. One jurisdiction, advanced in this process, therefore yielded the majority of data. Within 
the sample there was considerable agreement among the narratives across the recruitment sites, 
indicating that the sample size in this study, while small, was appropriate for this exploratory 
nature of this work   
 
Conclusion  
Understanding how knowledge is acquired about injecting new pharmaceutical formulations that 
are intended to reduce injection is crucial in developing more effective harm reduction strategies. 
The data illustrate different practices in preparing the film that do not reflect the best evidence, 
with respect to heating of water and use of wheel filters.  Participants reported peer-networks as 
a source of knowledge around these preparation practices, highlighting the opportunities for 





formulations.  Recommendations arising from the data gathered in this study include: further 
qualitative work on knowledge acquisition of injecting practices when new preparations of 
pharmaceutical opioids are introduced; and the specific ways in which peer-networks can be 
harnessed for the dissemination of harm reduction messages when novel preparations such as the 
film are introduced.  Although we are well aware of the harms resulting from intravenous use of 
tablets this study has described such use with a new formulation with an unusual texture that 
may result in a variety of harms not seen with injection of tablets and as such it is important to 
continue to monitor this behaviour. 
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